

Table 6. Summary of the relative potencies of the shuffled IFN- α and control compounds in the Th1 differentiation assay

Sample [†]	Mean log EC ₅₀	SD	<i>n</i>	Mean EC ₅₀ , ng/ml	Fold over IFN- α 2a [‡]	Fold over IFN- con1 [‡]	<i>P</i> value sample vs. IFN-con1
B9X16 *	-1.70	0.738	9	0.0199	42	15	<0.0001
B9X23 *	-1.45	0.483	7	0.0354	24	8.6	<0.0001
B9X25 *	-1.40	0.314	11	0.0395	21	7.7	<0.0001
B9X14 *	-1.31	0.408	12	0.0488	17	6.2	<0.0001
B9X28 *	-1.30	0.522	8	0.0496	17	6.1	<0.0001
B9X18 *	-1.16	0.774	4	0.0696	12	4.4	0.00157
B9X26 *	-1.11	0.948	3	0.0768	11	3.9	0.00744
B9.1.2 *	-1.03	0.166	2	0.0924	9.0	3.3	0.0467
B9X27 *	-1.03	0.357	3	0.0926	9.0	3.3	0.0199
B9X17 *	-0.930	0.857	4	0.118	7.1	2.6	0.0372
B9X22	-0.798	0.129	3	0.159	5.2	1.9	0.199
IFN-con1	-0.519	0.525	11	0.303	2.8	1.0	-
B9X12	-0.486	0.411	3	0.326	2.6	0.93	0.880
B9X15	-0.332	0.696	3	0.466	1.8	0.65	0.388
IFN- α 2a	-0.079	1.01	8	0.834	1.0	0.36	0.00572

The samples are listed in order of decreasing potency. The dash indicates not applicable.

[†] The mean log EC₅₀ values of those interferon samples marked with an asterisk are statistically different at the 95% confidence level from the mean log EC₅₀ value of IFN-con1 in the Th1 assay based on a two-way ANOVA (sample, donor) and Fisher's least significant difference post hoc test ($\alpha = 0.05$). Note that significant variations from donor to donor are reflected within the standard deviations. The *p* values indicate the confidence that the sample means are different from each other. B9X14 and B9X25 are significantly more potent than both IFN- α 2a and IFN-con1 by the Fisher LSD post-hoc test ($P < 0.0001$). B9X14 ($n = 12$) and B9X25 ($n = 11$) were significantly more potent than both IFN-con1 and IFN- α 2a in all donors.

[‡] Fold improvements were calculated as a ratio of mean EC₅₀ (ng/ml) values relative to IFN- 2a or IFN-con1.